JPRN-UMIN000041710招募中未知
Integrated genomic and epigenomic analysis of circulating tumor DNA from hepatocellular carcinoma patients - COSMOS-HCC-01
ational Cancer Center Hospital East0 个研究点目标入组 200 人开始时间: 2020年9月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. a history of malignancy (excluding intraepithelial cancer) with a disease-free period of 5 years or less. *1 2. Clinically diagnosed cancer of another organ. 3. the presence of multiple tumors for which different treatments of hepatic resection and ablation are contemplated for each. 4. Preoperative adjuvant therapy is contemplated prior to liver resection or ablation.*2 5.women who are pregnant or intend to become pregnant. 6. deemed unsuitable for enrollment in the study by the attending physician. *1 Even if the disease-free period is less than 5 years, a history of cancer with a 5-year relative survival rate equivalent to 95% or higher, such as stage I prostate cancer, stage 0 and stage I laryngeal cancer with complete response to radiotherapy, and the following pathological stages of cancer that have been completely resected, can be registered without exclusion. Gastric cancer (adenocarcinoma (general type)): stage 0-I, colon cancer (adenocarcinoma): stage 0-I, rectal cancer (adenocarcinoma): stage 0-I, esophageal cancer (squamous cell carcinoma, adenosquamous cell carcinoma, basal cell carcinoma): stage 0, breast cancer (non-invasive ductal carcinoma, non-invasive lobular carcinoma): stage 0, breast cancer (invasive ductal carcinoma, invasive lobular carcinoma, Paget's disease): stage 0-IIA Uterine cancer (endometrial adenocarcinoma, mucinous adenocarcinoma): stage IA, Prostate cancer (adenocarcinoma): stage I-II, Cervical cancer (squamous cell carcinoma): stage IA, Thyroid cancer (papillary carcinoma, follicular carcinoma): stage I, II, III, Renal cancer (panniculocarcinoma, anaplastic pigment cell carcinoma): stage I, Other intramucosal cancer equivalent lesions *2 Postoperative adjuvant therapy after liver resection or ablation is contemplated is acceptable.
研究者
相似试验
已完成
不适用
Integrated genomic and epigenomic analysis of circulating tumor DNA from patients with malignant melanomaJPRN-UMIN000042040ational Cancer Center Hospital East50
招募中
不适用
Integrated genomic and epigenomic analysis of circulating tumor DNA from patients with BRAF V600-mutant melanomamalignant melanomaJPRN-UMIN000051210ational Cancer Center Hospital East50
已完成
不适用
Integrated genomic and epigenomic analysis of blood circulation tumor DNA from gastric cancer and gastric GIST patientsGastric cancer, GISTJPRN-UMIN000040148ational Cancer Center Hospital East600
已完成
不适用
Integrated genomic and epigenomic analysis of blood circulating tumor DNA for pancreatic cancerpancreatic cancerJPRN-UMIN000040470ational Cancer Center Hospital East500
招募中
Unknown
Integrated analysis of genomic and epigenomic alterations in circulating tumor DNA in patients with biliary tract cancerBiliary tract cancerJPRN-UMIN000052780ational Cancer Center Hospital East110